There's been a vast amount of work (and excitement) in the immunotherapy approaches to cancer in the last few years. Here's a report on one that I'd missed: IMM-101, which is not directed to PD-1 or PD-1L1, not an engineered T-cell, or any of the other things that have been in the news. It's a killed preparation of the bacterium Mycobacterium obuense, which mixture seems to have broad immunomodulatory activity.
Read Full Article »
